Skip to main content

Table 3 General estimating equation analysis summary of the association between alopecia and the 5 PRO measures in patients taking ripretinib

From: Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

 

Mean estimatea

Confidence interval

P-valueb

Alopecia

 EORTC QLQ-C30

   

  Overall health

0.17

(− 0.10, 0.44)

0.22

  Overall quality of life

0.35

(0.03, 0.67)

0.03

  Physical function

3.17

(− 0.29, 6.64)

0.07

  Role function

4.50

(− 2.87, 11.87)

0.23

 EQ-5D-5 L

  VAS

3.01

(− 0.64, 6.67)

0.11

  1. ECOG Eastern Cooperative Oncology Group, EORTC QLQ-C30 European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire, EQ-5D-5 L EuroQoL 5-Dimension 5-Level, PRO Patient-reported outcome, VAS Visual analogue scale
  2. aIndicates the impact on PRO score in patients receiving ripretinib with alopecia vs. patients receiving ripretinib without alopecia, while keeping other variables constant (i.e., gender and ECOG status)
  3. bAll P-values reported are nominal
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us